LaFleur Minerals reported strong gold assay results from its Swanson Gold Project, including 6.05 g/t Au over 8 meters near surface at the Bartec target, a new priority for follow-up drilling. Drilling also extended gold mineralization 1,200 meters at Jackson and found multiple mineralized zones at Jolin, highlighting the project's district-scale potential. The company plans further drilling to explore continuity and expand resources, aiming to develop large-scale gold deposits in the prolific Abitibi Gold Belt.
LaFleur Minerals reported strong gold assay results at its Swanson Gold Project. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 05, 2026 17:42 WIB: 22 of 38 US Basic Materials stocks rose, 15 fell. Dow Inc traded at USD 27.79 with a -0.64% change, BHP Billiton Limited at USD 85.54 down -0.62%, and DuPont de Nemours Inc rose 0.61% to USD 130.77. Typical hold times ranged from 82 to 142 days on Pluang.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
